Bolsonaro signs law allowing SUS to prescribe drugs without Anvisa approval

Shift of pharmaceutical approval authority from independent regulator (Anvisa) to health ministry committee (Conitec), concentrating executive power. May influence regional regulatory precedents and pharmaceutical industry lobbying strategies in Latin America. Potential tension between national sovereignty and international pharmaceutical standards.

Similar to regulatory rollbacks in other countries where political actors bypass independent agencies; comparable to debates over drug approval timelines in the US (right-to-try laws) but with weaker safeguards.

Patients gain potential access to additional treatment options for conditions where off-label use shows scientific merit, but face increased risk if safety oversight is weakened. Lower-income populations using SUS may benefit from cost-effective alternatives, though quality assurance becomes critical.

This represents regulatory liberalization that bypasses Anvisa's traditional approval pathway, potentially creating tension between drug safety standards and treatment access. May prompt Anvisa to strengthen post-market surveillance and Conitec evaluation criteria. Could influence international pharmaceutical trade negotiations and set precedent for other emerging markets.